Novavax Inc reports results for the quarter ended December 31 - Earnings Summary

• Novavax Inc NVAX.OQ reported a quarterly adjusted loss of 83 cents​​ per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of $-1.44. The mean expectation of five analysts for the quarter was for a loss of 51 cents per share. Wall Street expected results to range from $-1.09 to 46 cents per share.

• Revenue fell 52.8% to $88.31 million from a year ago; analysts expected $84.38 million.

• Novavax Inc's reported EPS for the quarter was a loss of 76 cents​.

• The company reported a quarterly loss of $81.03 million.

• Novavax Inc shares had fallen by 9.0% this quarter.

FORECAST CHANGES

• The mean earnings estimate of analysts was unchanged in the last three months.​

• In the last 30 days, there have been no negative revisions of earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," 2 "hold" and 1 "sell" or "strong sell."

• The average consensus recommendation for the biotechnology & medical research peer group is "hold."

Wall Street's median 12-month price target for Novavax Inc is $19.00

This summary was machine generated from LSEG data February 27 at 03:23 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)